Immunotherapy of Prostate Cancer Patients could Overexpress The Virulence Factor Genes of E.faecalis

Prostate cancer is the most prevalent and second cause of death from cancer in

men worldwide. Immunotherapy is a new method for the treatment of several cancers

that fights cancer cells by strengthening the immune system through some medications.

While immunotherapy is a useful method for cancer treatment; its’ side effects still are

not totally clarified. Numbers of prostate cancer patients which take immunotherapy are

experiencing prostate inflammation and prostatitis after treatment period.

Enterococcus faecalis is Gram-positive and catalase-negative cocci that are common

in the intestines of humans and other animals and cause most enterococcal infections such as intestinal

infections, prostatitis, gastroenteritis and endocarditic. Present study aimed to evaluate the mRNA level of virulence genes which are involved in Enterococcus faecalis pathogenesis in prostate cancer patients that treated by immunotherapy. Expression level of gelatinase E (gelE) and Enterococcal surface protein (

esp genes were examined by Real time PCR in three groups of 68 male subjects. Group A normal subjects, group B prostate cancer patients before start treatment and group C prostate cancer patients after six months immunotherapy period.

for more details on article visit: http://edelweisspublications.com/edelweiss/article/Immunotherapy-Prostate-Cancer-Patients-could-Overexpress-Virulence-Factor-Genes-E.faecalis-ECOA-17-103.pdf